Published in Expert Opin Investig Drugs on October 01, 2010
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res (2012) 1.04
Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate (2011) 0.94
Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev (2014) 0.92
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 0.92
Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol (2013) 0.91
Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer (2013) 0.83
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag (2014) 0.80
Bone-targeting agents in prostate cancer. Cancer Metastasis Rev (2014) 0.80
Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction. J Biol Chem (2011) 0.78
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget (2014) 0.77
Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects. Ther Adv Urol (2016) 0.77
4-Hy-droxy-5-meth-oxy-N,1-dimethyl-2-oxo-N-[4-(tri-fluoro-meth-yl)phen-yl]-1,2-di-hydro-quinoline-3-carboxamide. Acta Crystallogr Sect E Struct Rep Online (2014) 0.75
A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) (2016) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
The role of angiogenesis in tumor growth. Semin Cancer Biol (1992) 5.33
A history of prostate cancer treatment. Nat Rev Cancer (2002) 2.46
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol (2009) 1.65
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem (2004) 1.55
Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology (2000) 1.52
Androgen receptor outwits prostate cancer drugs. Nat Med (2004) 1.44
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol (2007) 1.41
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol (2002) 1.24
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res (1997) 1.20
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer (2010) 1.14
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate (2006) 1.13
Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res (1995) 1.11
Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res (2005) 1.10
Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol (1985) 1.06
Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res (1982) 1.04
Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle (2004) 1.03
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer (2009) 1.01
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator. Arthritis Rheum (1986) 0.97
Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res (1993) 0.97
Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res (1986) 0.95
Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol (1993) 0.95
Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice. Immunology (1986) 0.95
The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res (1992) 0.94
Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res (1989) 0.93
Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology (1996) 0.90
Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs (2009) 0.90
Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res (1995) 0.87
Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation (1992) 0.86
Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer. Cancer Chemother Pharmacol (2007) 0.85
Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult Scler (2000) 0.85
A treatment for metastasis of murine ocular melanoma. Invest Ophthalmol Vis Sci (1988) 0.82
Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. J Urol (1997) 0.81
The effect of linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor. Br J Pharmacol (1996) 0.81
Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology (1996) 0.81
EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors. Eur J Cancer (1997) 0.80
Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res (1996) 0.80
An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma. Eur J Cancer (1997) 0.79
Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants. Br J Cancer (1998) 0.78
Phase I study in malignancy of LS 2616, a new immunomodulator: methodological considerations. Cancer Detect Prev (1988) 0.78
The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol (1994) 0.77
Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Xenobiotica (2000) 0.77
Stimulation of wound healing by the immunomodulator LS-2616 (Linomide). World J Surg (1995) 0.77
Inhibition of angiogenesis and metastases of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide. Anticancer Res (1995) 0.77